
News|Articles|October 8, 2026
September 2026 retina recap: Pivotal readouts and the MOGENRY BLA
Author(s)Kassi Filkins
Pivotal wet AMD, DME, and XLRP readouts; the MOGENRY BLA; and Retina Society, EURETINA, and ESCRS highlights from September.
Advertisement
Advertisement
September was a readout month for retina. Without a single FDA approval in the specialty, the news was driven by topline phase 3 data in wet AMD and DME, a pivotal gene therapy win in X-linked retinitis pigmentosa (XLRP), and the Retina Society 59th Annual Scientific Meeting in Los Angeles (September 23 to 26), where several programs presented their first or longest-term data. The BLA acceptance for
Related to this article

A longer axial length in the fellow eye of that treated for a rhegmatogenous retinal detachment was associated with a greater risk of a total retinal detachment.

Josef Huemer, MD, discusses retinal changes linked to atrial fibrillation and what they mean for eye care clinicians.

The first-in-human study of the GalNAc-conjugated siRNA joins a fast-moving Stargardt pipeline as the FDA weighs the first potential approval for the disease.

VeonGen aligns with FDA on phase 3 design for VG801, a dual-AAV Stargardt gene therapy, after uncontrolled phase 1/2 BCVA gains.

James Deom, OD, MPH, FAAO, FSLS, of Hazleton Eye Specialists, explains his baseline imaging approach, his nocturnal hypotension hypothesis and his same-day workup for patients on GLP-1 RAs who have sudden vision loss.

A first-in-class small-molecule Fas inhibitor delivered by intravitreal injection is now under evaluation in more than 324 patients across North America and Europe.
Advertisement
Advertisement


